株探米国株
英語
エドガーで原本を確認する

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

For the Month of May 2025

 

Commission File Number 001-35948

 

Kamada Ltd.

(Translation of registrant’s name into English)

 

2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Israel
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

 

 

 


 

This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

 

1


 

The following exhibit is attached:

 

99.1   Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability
     
99.2   Company’s Presentation – May 2025
     
99.3   Kamada Ltd’s Condensed Consolidated Interim Financial Statements as of March 31, 2025 (Unaudited)
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 14, 2025 KAMADA LTD.
   
  By: /s/ Nir Livneh
   

Nir Livneh

Vice President General Counsel and
Corporate Secretary

 

3


 

EXHIBIT INDEX

 

EXHIBIT NO.   DESCRIPTION
99.1   Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability
     
99.2   Company’s Presentation – May 2025
     
99.3   Kamada Ltd’s Condensed Consolidated Interim Financial Statements as of March 31, 2025 (Unaudited)
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

4

 

EX-99.1 2 ea024084701ex99-1_kamada.htm KAMADA REPORTS STRONG FIRST QUARTER 2025 FINANCIAL RESULTS WITH YEAR OVER YEAR TOP LINE GROWTH OF 17% AND A 54% INCREASE IN PROFITABILITY

Exhibit 99.1

 

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth
of 17% and a 54% Increase in Profitability

 

Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year Increase

 

First Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-Year

 

Strong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities

 

Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, Texas

 

Launched Comprehensive Post-Marketing Research Program of CYTOGAM®

 

Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year

 

Conference Call and Live Webcast Today at 8:30am ET

 

REHOVOT, Israel, and HOBOKEN, NJ – May 14, 2025 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months ended March 31, 2025.

 

“Results for the first quarter of 2025 were in line with our expectations and consistent with the strong operational and commercial performance we generated over the course of the previous year,” said Amir London, Kamada’s Chief Executive Officer. “Total revenues for the first quarter were $44.0 million, representing an increase of approximately 17% year-over-year, and adjusted EBITDA was $11.6 million, an increase of approximately 54% year-over-year. We continue to generate profitable growth through the diversity of our portfolio and disciplined management of operational expenses. We are reiterating our 2025 annual guidance of $178 million to $182 million in revenues, and $38 million to $42 million of adjusted EBITDA.”

 

“We continue to invest in our four strategic growth pillars, consisting of organic commercial growth, business development and M&A transactions, our plasma collection operations, and advancement of our pivotal Phase 3 Inhaled AAT program. We were pleased to announce last week the initiation of a comprehensive post-marketing research program for CYTOGAM®, which we believe will further demonstrate the various benefits of the product in the prevention and management of cytomegalovirus (CMV) disease in solid organ transplantation. We believe that the data generated by this program will support additional product utilization in the coming years,” added Mr. London.

 

“Based on our ongoing business development initiatives, we expect to secure compelling opportunities to enrich our portfolio of marketed products, complement our existing commercial operations and support our continued profitable growth. During the quarter, we also expanded our plasma collection operations with the opening of our third center located in San Antonio, TX. Once at full collection capacity, we anticipate that each of our Houston and San-Antonio collection centers will contribute annual revenues of $8 million to $10 million through sales of normal source plasma. Lastly, we continue to advance our ongoing pivotal Phase 3 InnovAATe clinical trial for our inhaled Alpha-1 Antitrypsin therapy. Enrollment is progressing, and we are on track to conduct an interim futility analysis by the end of 2025,” concluded Mr. London.

 

Financial Highlights for the Three Months Ended March 31, 2025

 

Total revenues were $44.0 million in the first quarter of 2025, up 17% compared to $37.7 million in the first quarter of 2024. The increase in revenues was driven by the diversity of our portfolio, primarily attributable to increased sales of GLASSIA® and KAMRAB® in ex U.S. markets, as well as sales of VARIZIG® and royalty income from GLASSIA.

 

Gross profit and gross margins were $20.7 million and 47%, respectively, in the first quarter of 2025, compared to $16.8 million and 44%, respectively, in the first quarter of 2024. The increase in both metrics is attributable to improved product sales mix.

 

Operating expenses, including R&D, S&M, G&A and other expenses, totaled $13.0 million in the first quarter of 2025, as compared to $12.7 million in the first quarter of 2024. The marginal increase in operating expenses is indicative of the Company’s ability to adequately manage its operational spend while continuing to generate meaningful revenue growth.

 

 


 

Net income was $4.0 million, or $0.07 per diluted share, in the first quarter of 2025, as compared to $2.4 million, or $0.04 per diluted share, in the first quarter of 2024.

 

Adjusted EBITDA, as detailed in the tables below, was $11.6 million in the first quarter of 2025, up 54% from the $7.5 million reported in the first quarter of 2024.

 

Cash used in operating activities was $0.5 million in the first quarter of 2025, as compared to cash provided by operating activities of $1.0 million in the first quarter of 2024. Cash used in operating activities during the first quarter of 2025 was affected by an increase in working capital in support of continued growth.

 

Balance Sheet Highlights

 

As of March 31, 2025, the Company had cash and cash equivalents of $76.3 million, as compared to $78.4 million as of December 31, 2024.

 

Recent Corporate Highlights

 

Announced the launch of a new post-marketing research program aimed at generating key data in support of the benefits of CYTOGAM® in the management of cytomegalovirus (CMV) in solid organ transplantation. The research program, developed in collaboration with multiple leading Key Opinion Leaders (KOLs), is directed at advancing CMV disease management through novel strategies focused on late-onset CMV prevention and mitigation of active CMV disease, exploring alternative dosing strategies, and investigating potential new applications of CYTOGAM.

 

Announced the expansion of the Company’s plasma collection operations with the opening of a third plasma collection center. The new 11,100 square foot center in San Antonio, TX, is operated by Kamada’s wholly owned subsidiary, Kamada Plasma, and is planned to support once fully operational close to 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually. The new center is expected to contribute annual revenues of $8 million to $10 million through sales of normal source plasma at its full capacity.

 

Announced the award of a contract with an international organization for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027. Total expected revenue under the three-year contract for both products is estimated to be approximately $25 million. The expected portion for the calendar year 2025 is incorporated into the Company’s 2025 revenue guidance.

 

Fiscal 2025 Guidance

 

Kamada continues to expect to generate fiscal year 2025 total revenues in the range of $178 million to $182 million, and adjusted EBITDA in the range of $38 million to $42 million, representing a year-over-year increase of approximately 12% in revenues and 17% in adjusted EBITDA based on the mid-point of the 2025 guidance.

 

Conference Call Details

 

Kamada management will host an investment community conference call on Wednesday, May 14 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 1375314. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1715006&tp_key=c9896a4811. 

 

2


 

Non-IFRS financial measures

 

We present EBITDA and adjusted EBITDA because we use these non-IFRS financial measures to assess our operational performance, for financial and operational decision-making, and as a means to evaluate period-to-period comparisons on a consistent basis. Management believes these non-IFRS financial measures are useful to investors because: (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and provide investors with a meaningful perspective on the current underlying performance of the Company’s core ongoing operations; and (2) they exclude the impact of certain items that are not directly attributable to our core operating performance and that may obscure trends in the core operating performance of the business. Non-IFRS financial measures have limitations as an analytical tool and should not be considered in isolation from, or as a substitute for, our IFRS results. We expect to continue reporting non-IFRS financial measures, adjusting for the items described below, and we expect to continue to incur expenses similar to certain of the non-cash, non-IFRS adjustments described below. Accordingly, unless otherwise stated, the exclusion of these and other similar items in the presentation of non-IFRS financial measures should not be construed as an inference that these items are unusual, infrequent or non-recurring. EBITDA and adjusted EBITDA are not recognized terms under IFRS and do not purport to be an alternative to IFRS terms as an indicator of operating performance or any other IFRS measure. Moreover, because not all companies use identical measures and calculations, the presentation of EBITDA and adjusted EBITDA may not be comparable to other similarly titled measures of other companies. EBITDA is defined as net income (loss), plus income tax expense, plus or minus financial income or expenses, net, plus or minus income or expense in respect of securities measured at fair value, net, plus or minus income or expenses in respect of currency exchange differences and derivatives instruments, net, plus depreciation and amortization expense, whereas adjusted EBITDA is the EBITDA plus non-cash share-based compensation expenses and certain other costs.

 

For the projected 2025 adjusted EBITDA information presented herein, the Company is unable to provide a reconciliation of this forward measure to the most comparable IFRS financial measure because the information for these measures is dependent on future events, many of which are outside of the Company’s control. Additionally, estimating such forward-looking measures and providing a meaningful reconciliation consistent with the Company’s accounting policies for future periods is meaningfully difficult and requires a level of precision that is unavailable for these future periods and cannot be accomplished without unreasonable effort. Forward-looking non-IFRS measures are estimated in a manner consistent with the relevant definitions and assumptions noted in the Company’s adjusted EBITDA for historical periods.

 

About Kamada

 

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First: organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston, Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of outstanding ordinary shares.

 

3


 

Cautionary Note Regarding Forward-Looking Statements

 

This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) double digit growth in fiscal year 2025, 2) reiteration of 2025 full-year revenue guidance of $178 million to $182 million and adjusted EBITDA of $38 million to $42 million, 3) expectation to continue investing in the Company's four strategic growth pillars, consisting of organic commercial growth, business development and M&A transactions, our plasma collection operations, and advancement of our pivotal Phase 3 Inhaled AAT program, 4) the ability of the post-marketing research program for CYTOGAM to generate key data in support of the benefits of CYTOGAM in the prevention and management of CMV in solid organ transplantation, 5) increased utilization of CYTOGAM as a result of positive results from the program or otherwise, 6) expectation to secure compelling opportunities to enrich our portfolio of marketed products, complement our existing commercial operations and support our continued profitable growth, 7) new plasma collection center in San Antonio is planned to support close to 50 donor beds and has planned annual collection capacity of approximately 50,000 liters, 8) expected annual revenues contribution from sales of normal source plasma collected in each of the Houston and the San-Antonio collection centers at $8 million to $10 million at full capacity, 9) continued progress of the InnovAATe clinical trial and conducting an interim futility analysis by the end of 2025, 10) estimation that total revenue under the three-year contract for sales of KAMRAB and VARIZIG in Latin America for 2025-2027 be approximately $25 million; and 11) strong financial position to accelerate growth through M&A and/or in-licensing opportunities. Forward-looking statements are based on Kamada’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to the evolving nature of the conflicts in the Middle East and the impact of such conflicts in Israel, the Middle East and the rest of the world, the impact of these conflicts on market conditions and the general economic, industry and political conditions in Israel, the U.S. and globally, effect of potential imposed tariff on overall international trade and specifically on Kamada’s ability to continue maintaining expected sales and profit levels in light of such potential tariff, the effect on establishment and timing of business initiatives, Kamada’s ability to leverage new business opportunities, including M&A and in-license opportunities and integrate it with its existing product portfolio, operational capabilities of Kamada’s plasma centers, unexpected results of clinical and development programs, regulatory delays, and other risks detailed in Kamada’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including those discussed in its most recent Annual Report on Form 20-F and in any subsequent reports on Form 6-K, each of which is on file or furnished with the SEC and available at the SEC’s website at www.sec.gov. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

 

CONTACTS:

 

Chaime Orlev

Chief Financial Officer

IR@kamada.com

 

Brian Ritchie

LifeSci Advisors, LLC

212-915-2578

britchie@LifeSciAdvisors.com

 

4


 

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

    As of     As of  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited        
    U.S. Dollars in Thousands  
Assets                  
Current Assets                  
Cash and cash equivalents   $ 76,250     $ 48,194     $ 78,435  
Trade receivables, net     27,876       18,855       21,547  
Other accounts receivables     6,016       6,411       5,546  
Inventories     78,358       84,348       78,819  
Total Current Assets     188,500       157,808       184,347  
                         
Non-Current Assets                        
Property, plant and equipment, net     37,406       30,727       36,245  
Right-of-use assets     9,539       7,632       9,617  
Intangible assets and other long-term assets     101,422       108,310       103,226  
Goodwill     30,313       30,313       30,313  
Contract assets     7,925       8,384       8,019  
Deferred taxes     -       -       488  
Total Non-Current Assets     186,605       185,366       187,908  
Total Assets   $ 375,105     $ 343,174     $ 372,255  
Liabilities                        
Current Liabilities                        
Current maturities of lease liabilities   $ 1,780     $ 1,467     $ 1,631  
Current maturities of other long term liabilities     10,889       12,980       10,181  
Trade payables     24,854       16,492       27,735  
Other accounts payables     19,319       6,210       9,671  
Deferred revenues     205       26       171  
  Total Current Liabilities     57,047       37,175       49,389  
                         
Non-Current Liabilities                        
Lease liabilities     9,318       7,278       9,431  
Contingent consideration     21,216       16,760       20,646  
Other long-term liabilities     32,990       34,842       32,816  
Deferred taxes     2,061       -       -  
Employee benefit liabilities, net     516       609       509  
Total Non-Current Liabilities     66,101       59,489       63,402  
                         
Shareholder’s Equity                        
Ordinary shares     15,074       15,022       15,028  
Additional paid in capital net     268,160       266,183       266,933  
Capital reserve due to translation to presentation currency     (3,490 )     (3,490 )     (3,490 )
Capital reserve from hedges     (117 )     12       51  
Capital reserve from share-based payments     5,266       6,336       6,316  
Capital reserve from employee benefits     372       282       364  
Accumulated deficit     (33,308 )     (37,835 )     (25,738 )
Total Shareholder’s Equity     251,957       246,510       259,464  
Total Liabilities and Shareholder’s Equity   $ 375,105     $ 343,174     $ 372,255  

 

5


 

CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

 

    Three months period ended     Year ended  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited        
    U.S. Dollars in Thousands  
Revenues from proprietary products   $ 40,017     $ 33,758     $ 141,447  
Revenues from distribution     4,001       3,978       19,506  
                         
Total revenues     44,018       37,736       160,953  
                         
Cost of revenues from proprietary products     19,738       17,620       73,708  
Cost of revenues from distribution     3,531       3,365       17,278  
                         
Total cost of revenues     23,269       20,985       90,986  
                         
Gross profit     20,749       16,751       69,967  
                         
Research and development expenses     4,246       4,295       15,185  
Selling and marketing expenses     4,510       4,631       18,428  
General and administrative expenses     4,198       3,786       15,702  
Other expenses     -       -       601  
Operating income (loss)     7,795       4,039       20,051  
                         
Financial income     534       280       2,118  
Income (expenses) in respect of currency exchange differences and derivatives instruments, net     251       124       (94 )
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.     (1,775 )     (1,845 )     (8,081 )
Financial expenses     (192 )     (159 )     (660 )
Income before tax on income     6,613       2,439       13,334  
Taxes on income     (2,649 )     (74 )     1,128  
                         
Net Income (loss)   $ 3,964     $ 2,365     $ 14,462  
                         
Other Comprehensive Income (loss):                        
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met                        
Gain (loss) on cash flow hedges     (114 )     (71 )     (30 )
Net amounts transferred to the statement of profit or loss for cash flow hedges     (54 )     (57 )     (59 )
Items that will not be reclassified to profit or loss in subsequent periods:                        
Remeasurement gain (loss) from defined benefit plan     8       7       89  
Total comprehensive income (loss)   $ 3,804     $ 2,244     $ 14,462  
                         
Earnings per share attributable to equity holders of the Company:                        
Basic net earnings per share   $ 0.07     $ 0.04     $ 0.25  
Diluted net earnings per share   $ 0.07     $ 0.04     $ 0.25  

 

6


 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

 

    Three months period Ended     Year Ended  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited     Unaudited        
    U.S. Dollars in Thousands  
Cash Flows from Operating Activities                  
Net income (loss)   $ 3,964     $ 2,365     $ 14,462  
                         
Adjustments to reconcile net income to net cash provided by (used in) operating activities:                        
                         
Adjustments to the profit or loss items:                        
                         
Depreciation and amortization     3,611       3,237       13,808  
Financial expenses, net     1,182       1,600       6,717  
Cost of share-based payment     175       241       874  
Taxes on income     2,649       74       (1,128 )
Loss (gain) from sale of property and equipment     (8 )     -       11  
Change in employee benefit liabilities, net     16       (4 )     52  
      7,625       5,148       20,334  
Changes in asset and liability items:                        
                         
Decrease (increase) in trade receivables, net     (6,557 )     610       (1,977 )
Decrease (increase) in other accounts receivables     (671 )     (516 )     593  
Decrease in inventories     461       4,131       9,659  
Decrease in deferred expenses     94       112       476  
Increase (decrease) in trade payables     (3,748 )     (8,785 )     1,226  
Increase (decrease) in other accounts payables     (2,044 )     (2,051 )     1,413  
Increase (decrease) in deferred revenues     34       (122 )     23  
      (12,431 )     (6,621 )     11,413  
Cash received (paid) during the period for:                        
                         
Interest paid     (176 )     (129 )     (594 )
Interest received     534       280       2,118  
Taxes paid     (29 )     (23 )     (139 )
      329       128       1,385  
                         
Net cash provided by (used in) operating activities   $ (513 )   $ 1,020     $ 47,594  

 

7


 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (continued)

 

    Three months period Ended     Year Ended  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited     Unaudited        
    U.S. Dollars in Thousands  
Cash Flows from Investing Activities                  
Purchase of property and equipment and intangible assets   $ (1,468 )   $ (2,682 )   $ (10,740 )
Proceeds from sale of property and equipment     8       -       1  
Net cash used in investing activities     (1,460 )     (2,682 )     (10,739 )
                         
Cash Flows from Financing Activities                        
                         
Proceeds from exercise of share base payments     46       1       7  
Proceeds from issuance of ordinary shares, net     -       -       -  
Repayment of lease liabilities     (14 )     (244 )     (1,251 )
Repayment of long-term loans     -       -       -  
Repayment of other long-term liabilities     (325 )     (5,496 )     (12,667 )
Net cash used in financing activities     (293 )     (5,739 )     (13,911 )
                         
Exchange differences on balances of cash and cash equivalent     81       (46 )     (150 )
                         
Increase (decrease) in cash and cash equivalents     (2,185 )     (7,447 )     22,794  
                         
Cash and cash equivalents at the beginning of the period     78,435       55,641       55,641  
                         
Cash and cash equivalents at the end of the period   $ 76,250     $ 48,194     $ 78,435  
                         
Significant non-cash transactions                        
Right-of-use asset recognized with corresponding lease liability   $ 352     $ 306     $ 3,304  
Purchase of property and equipment and Intangible assets   $ 1,103     $ 905     $ 1,955  

 

8


 

NON-IFRS MEASURES

 

    Three months period Ended     Year Ended  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited     Unaudited        
    U.S. Dollars in Thousands  
Net income   $ 3,964     $ 2,365     $ 14,462  
Taxes on income     2,649       74       (1,128 )
Financial expense, net     1,182       1,600       6,717  
Depreciation and amortization expense     3,611       3,237       13,218  
Non-cash share-based compensation expenses     175       241       867  
Adjusted EBITDA   $ 11,581     $ 7,517     $ 34,136  

 

9

 

EX-99.2 3 ea024084701ex99-2_kamada.htm COMPANY'S PRESENTATION - MAY 2025

Exhibit 99.2

 

 


May 2025 First Quarter March 31, 2025 Investors Call FORWARD - LOO K I NG STATEM ENT This presentation is not intended to provide investment or medical advice . It should be noted that some products under development described herein have not been found safe or effective by any regulatory agency and are not approved for any use outside of clinical trials . This presentation contains forward - looking statements, which express the current beliefs and expectations of Kamada’s management . Such statements include 2025 financial guidance ; growth strategy and plans for double digit growth ; growth prospects related to the Israeli distribution business segment ; success in identifying and integrating M&A targets for growth ; advancement and future expected revenues driven by our plasma collection operation ; and continued progression of the inhaled AAT clinical study, its benefits and advantages, potential market size, reduction of the study sample to approximately 180 patients, and the plan to conduct an interim futility analysis by the end of 2025 . These statements involve a number of known and unknown risks and uncertainties that could cause Kamada's future results, performance or achievements to differ significantly from the projected results, performances or achievements expressed or implied by such forward - looking statements . Important factors that could cause or contribute to such differences include, but are not limited to, risks relating to Kamada's ability to successfully develop and commercialize its products and product candidates, progress and results of any clinical trials, introduction of competing products, continued market acceptance of Kamada’s commercial products portfolio, impact of geo - political environment in the middle east, impact of any changes in regulation and legislation that could affect the pharmaceutical industry, difficulty in predicting, obtaining or maintaining U . S . Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, restrains related to third parties’ IP rights and changes in the health policies and structures of various countries, success of M&A strategies, environmental risks, changes in the worldwide pharmaceutical industry and other factors that are discussed under the heading “Risk Factors” of Kamada’s 2024 Annual Report on Form 20 - F (filed on March 5 , 2025 ), as well as in Kamada’s recent Forms 6 - K filed with the U . S . Securities and Exchange Commission . This presentation includes certain non - IFRS financial information, which is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS . The non - IFRS financial measures may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies . In accordance with the requirement of the SEC regulations a reconciliation of these non - IFRS financial measures to the comparable IFRS measures is included in an appendix to this presentation . Management uses these non - IFRS financial measures for financial and operational decision - making and as a means to evaluate period - to - period comparisons . Management believes that these non - IFRS financial measures provide meaningful supplemental information regarding Kamada’s performance and liquidity . Forward - looking statements speak only as of the date they are made, and Kamada undertakes no obligation to update any forward - looking statement to reflect the impact of circumstances or events that arise after the date the forward - looking statement was made, except as required by applicable law .

 


GROSS MARGIN REVENUE 3bp 2024 44% 2025 47% 17% 2024 $37.7 2025 $44.0 Adj.

 


EBITDA EPS 54% 2024 $7.5 2025 $11.6 75% 2024 $0.04 2025 $0.07 Q1 - 25 CONTINUING THE GROWTH YoY DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE Paid special cash dividend of $0.20 per share (totaling approximately $11.5M) on April 7, 2025 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS KEDRAB® [Rabies Immune Globulin (Human)] Post exposure prophylaxis of rabies infection CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants HEPGAM B® [Hepatitis B Immune Globulin (Human)] Prevention of HBV recurrence following liver transplants VARIZIG® [Varicella Zoster Immune Globulin (Human)] Post - exposure prophylaxis of varicella in high - risk patients WINRHO® [Rho(D) Immune Globulin (Human)] Treatment of ITP & suppression of Rh isoimmunization (HDN) For Important Safety Information, visit www.Kamada.com GLASSIA® [Alpha1 - Proteinase Inhibitor (Human)] Augmentation therapy for Alpha - 1 Antitrypsin Deficiency (AATD)

 


6 18 24 34 38 - 42 2021 2022 2023 2024 2025 2025 represents annualguidance 104 129 142 161 1 78 - 182 2021 2022 2023 2024 2025 2025 represents annualguidance ADJUSTED EBITDA US$M 61% CAGR ANNUAL DOUBLE - DIGIT GROWTH TRAJECTORY REVENUES US$M 15% CAGR Quarter - End Strong Cash Position of $76.3 Million (pre dividend payment)

 


DELIVERING ON OUR COMMITMENTS

 


 


KAMADA’S ROADMAP FOR CONTINUED ANNUAL DOUBLE - DIGIT GROWTH M &A T r a ns a c ti o n s Support growth through M&A transactions Organic Growth Portfolio of 6 FDA - approved products; Over 30 territories; and Distribution portfolio in Israel Plasma C o l l e c ti o n Centers Each new center expected to contribute annual revenues of $8M - $10M at peak capacity Inhaled AAT Phase III pivotal clinical study, targeting a market of over $2B CYTOGAM CMV IMMUNE GLOBULIN CYTOGAM is the only plasma - derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause for organ rejection post - transplant Launched, in collaboration with multiple KOLs, a post - marketing research program aimed at generating key data in support of the benefits of CYTOGAM in the management of CMV in solid organ transplantation. Advancing CMV disease management through novel strategies focused on late - onset CMV prevention, active CMV disease mitigation, exploring alternative dosing strategies, and investigating potential new applications. $23M 2024 Revenues; Up 31% over 2023 Growth Continued growth expected in the U.S.

 


and Canada markets For Important Safety Information, visit https://cytogam.com/ ; *Source: https://optn.transplant.hrsa.gov/ DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL FOR LEADING BIOPHARMACEUTICAL COMPANIES EXPENDING THE DISTRIBUTION SEGMENT MODEL TO THE MENA REGION Key areas: plasma - derived, respiratory, rare diseases, infectious diseases, biosimilar portfolio of several product candidates, mainly from Alvotech Biosimilar portfolio expected to generate annual sales of $15 - 20M within the next five years First biosimilar launched in Q1 - 2024 and two additional expected to be launched in Israel during 2025 Additional biosimilar products are expected to be launched in Israel over the coming years, at a rate of 1 - 3 products per year M&A TRANSACTIONS EXPECT TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS DURING 2025; LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Exploring strategic business development opportunities to identify potential acquisition or in - licensing to accelerate long - term growth Focusing on products synergistic to our existing commercial and/or production activities Strong financial position, commercial infrastructure and proven successful M&A capabilities

 


 


 


KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Operating three plasma collection centers in Texas; Houston, San Antonio and Beaumont At full collection capacity, each of the Houston and San Antonio centers is expected to generate annual revenues of $8M to $10M from sales of NSP FDA reconfirmed overall study design, endorsed positive safety data to date, and confirmed its agreement with our proposed P - value of 0.1 in evaluating the trial’s efficacy primary endpoint $2 Billion A substantial market opportunity (2028) 1 Based on expected changes to the statistical analysis plan, intend to reduce the study sample size to approximately 180 patients , and conduct an interim futility analysis by the end of 2025 INHALED AAT PHASE 3 PIVOTAL STUDY I n n o v A A T e - a global,double - b li n d , r a ndo mi ze d , placebo - c o n tr o ll e d pivotalPhase 3 c l i ni c a l t r i a l t e s t i n g the safety and efficacy of inhaled AAT in patients with AATD. Study design meets FDA and EM A’s requirements 1.

 


Source: CantorFizgerald, JAN 11 2024 DETAILS Q1/24 Q1/25 US $ M Driven by KEDRAB®, VARIZIG®, GLASSIA® Royalties and GLASSIA sales 33.8 40.0 PROPRIETARY 4.0 4.0 DISTRIBUTION 17% YoY increase 37.7 44.0 TOTAL REVENUES 16.8 20.7 GROSS PROFIT 3 basis point increase YoY 44% 47% GROSS MARGIN (12.7) (13.0) OPEX 2.4 4.0 NET PROFIT 54% YoY increase 7.5 11.6 Adjusted EBITDA March 25 cash prior to dividend payment (approx. $11.5M) 48.2 76.3 CASH Including acquisition related intangible assets ($127M @ March 25) 343.2 375.1 TOTAL ASSETS Increase associated with new plasma collection centers in the U.S. 8.7 11.1 LEASE LIABILITIES Acquisition related contingent consideration 64.6 65.1 CONTINGENT LIABILITIES March 25 equity net of declared dividend (approx. $11.5M) 246.5 252.0 EQUITY Available cash net of contingent and lease liabilities (25.1) (2.5) NET CASH (DEBT) Adjusted EBITDA is defined as net income, plus (i) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization; and (v) non - cash share - based compensation expenses STRONG Q1 - 25 FINANCIAL RESULTS KEDRAB ® CYTOGA M® HEPGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 15% CAGR (from 2021) $178 - 182M 2025 Revenues Guidance $38 - 42M 2025 Adj.

 


 


THANK YOU www.kamada.com

 


EBIDTA Guidance 4 Pillars of Growth A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF MARKETED PRODUCTS INDICATED FOR RARE AND SERIOUS CONDITIONS $ 76.3 M Cash @ Mar 31, 2025 Organic Growth M &A Transactions Inhaled AAT PivotalStudy Plasma Collection Centers NON - IFRS MEASURES – ADJUSTED EBITDA Q1/24 Q1/25 US $ M 2.4 4.0 NET PROFIT 0.1 2.6 TAXES ON INCOME 1.8 1.8 REVALUATION OF ACQUISITION RELATED CONTINGENT CONSIDERATION (0.2) (0.6) OTHER FINANCIAL EXPENSE, NET 1.8 1.8 AMORTIZATION OF ACQUISITION RELATED INTANGIBLE ASSETS 1.5 1.8 OTHER DEPRECIATION AND AMORTIZATION EXPENSES 0.2 0.2 NON - CASH SHARE - BASED COMPENSATION EXPENSES 7.5 11.6 ADJUSTED EBITDA Adjusted EBITDA is defined as net income, plus (i) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization; and (v) non - cash share - based compensation expenses

 

Exhibit 99.3

 

KAMADA LTD.

 

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

AS OF MARCH 31, 2025

 

TABLE OF CONTENTS

 

  Page
   
Condensed Consolidated interim Statements of Financial Position F-2
   
Condensed Consolidated interim Statements of Profit or Loss and Other Comprehensive Income F-3
   
Condensed Consolidated interim Statements of Changes in Equity F-4 - F-5
   
Condensed Consolidated interim Statements of Cash Flows F-6 - F-7
   
Notes to the Interim Consolidated Financial Statements F-8 - F-13

 

- - - - - - - - - - -

 

F-1


 

KAMADA LTD.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION

 

 

    As of     As of  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited      
    U.S. Dollars in Thousands  
Assets                  
Current Assets                  
Cash and cash equivalents   $ 76,250     $ 48,194     $ 78,435  
Trade receivables, net     27,876       18,855       21,547  
Other accounts receivables     6,016       6,411       5,546  
Inventories     78,358       84,348       78,819  
Total Current Assets     188,500       157,808       184,347  
                         
Non-Current Assets                        
Property, plant and equipment, net     37,406       30,727       36,245  
Right-of-use assets     9,539       7,632       9,617  
Intangible assets and other long-term assets     101,422       108,310       103,226  
Goodwill     30,313       30,313       30,313  
Contract assets     7,925       8,384       8,019  
Deferred taxes    
-
     
-
      488  
Total Non-Current Assets     186,605       185,366       187,908  
Total Assets   $ 375,105     $ 343,174     $ 372,255  
Liabilities                        
Current Liabilities                        
Current maturities of lease liabilities   $ 1,780     $ 1,467     $ 1,631  
Current maturities of other long term liabilities     10,889       12,980       10,181  
Trade payables     24,854       16,492       27,735  
Other accounts payables     19,319       6,210       9,671  
Deferred revenues     205       26       171  
  Total Current Liabilities     57,047       37,175       49,389  
                         
Non-Current Liabilities                        
Lease liabilities     9,318       7,278       9,431  
Contingent consideration     21,216       16,760       20,646  
Other long-term liabilities     32,990       34,842       32,816  
Deferred taxes    
2,061
     
-
     
-
 
Employee benefit liabilities, net     516       609       509  
Total Non-Current Liabilities     66,101       59,489       63,402  
                         
Shareholder’s Equity                        
Ordinary shares     15,074       15,022       15,028  
Additional paid in capital net     268,160       266,183       266,933  
Capital reserve due to translation to presentation currency     (3,490 )     (3,490 )     (3,490 )
Capital reserve from hedges     (117 )     12       51  
Capital reserve from share-based payments     5,266       6,336       6,316  
Capital reserve from employee benefits     372       282       364  
Accumulated deficit     (33,308 )     (37,835 )     (25,738 )
Total Shareholder’s Equity     251,957       246,510       259,464  
Total Liabilities and Shareholder’s Equity   $ 375,105     $ 343,174     $ 372,255  

 

The accompanying Notes are an integral part of the Consolidated Financial Statements.

 

F-2


 

KAMADA LTD.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

 

 

    Three months period ended     Year ended  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited      
    U.S. Dollars in Thousands  
Revenues from proprietary products   $ 40,017     $ 33,758     $ 141,447  
Revenues from distribution     4,001       3,978       19,506  
                         
Total revenues     44,018       37,736       160,953  
                         
Cost of revenues from proprietary products     19,738       17,620       73,708  
Cost of revenues from distribution     3,531       3,365       17,278  
                         
Total cost of revenues     23,269       20,985       90,986  
                         
Gross profit     20,749       16,751       69,967  
                         
Research and development expenses     4,246       4,295       15,185  
Selling and marketing expenses     4,510       4,631       18,428  
General and administrative expenses     4,198       3,786       15,702  
Other expenses    
-
     
-
      601  
Operating income (loss)     7,795       4,039       20,051  
                         
Financial income     534       280       2,118  
Income (expenses) in respect of currency exchange differences and derivatives instruments, net     251       124       (94 )
Financial Income (expense) in respect of contingent consideration and other long- term liabilities.     (1,775 )     (1,845 )     (8,081 )
Financial expenses     (192 )     (159 )     (660 )
Income before tax on income     6,613       2,439       13,334  
Taxes on income     (2,649 )     (74 )     1,128  
                         
Net Income (loss)   $ 3,964     $ 2,365     $ 14,462  
                         
Other Comprehensive Income (loss):                        
Amounts that will be or that have been reclassified to profit or loss when specific conditions are met                        
Gain (loss) on cash flow hedges     (114 )     (71 )     (30 )
Net amounts transferred to the statement of profit or loss for cash flow hedges     (54 )     (57 )     (59 )
Items that will not be reclassified to profit or loss in subsequent periods:                        
Remeasurement gain (loss) from defined benefit plan     8       7       89  
Total comprehensive income (loss)   $ 3,804     $ 2,244     $ 14,462  
                         
Earnings per share attributable to equity holders of the Company:                        
Basic net earnings per share   $ 0.07     $ 0.04     $ 0.25  
Diluted net earnings per share   $ 0.07     $ 0.04     $ 0.25  

 

The accompanying Notes are an integral part of the Consolidated Financial Statements.

 

F-3


 

KAMADA LTD.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

 

 

          Additional     Capital
reserve
due to
translation to
    Capital
reserve
    Capital
reserve
from
    Capital
reserve
from
             
    Share     paid in     presentation     from     sharebased     employee     Accumulated     Total  
    capital     capital     currency     hedges     payments     benefits     deficit     equity  
    Unaudited  
    U.S. Dollars in Thousands  
Balance as of January 1, 2025 (audited)   $ 15,028     $ 266,933     $ (3,490 )   $ 51     $ 6,316     $ 364     $ (25,738 )   $ 259,464  
Net income    
-
     
-
     
-
     
-
     
-
     
-
      3,964       3,964  
Other comprehensive income (loss), net of tax    
-
     
-
     
-
      (168 )    
-
      8      
-
      (160 )
Total comprehensive income (loss)    
-
     
-
     
-
      (168 )    
-
      8       3,964       3,804  
Exercise and forfeiture of share-based payment into shares     46       1,227      
-
     
-
      (1,227 )    
-
     
-
      46  
Cost of share-based payment    
-
     
-
     
-
     
-
      177      
-
     
-
      177  
Dividend    
-
     
-
     
-
     
-
     
-
     
-
      (11,534 )     (11,534 )
Balance as of March 31, 2025   $ 15,074     $ 268,160     $ (3,490 )   $ (117 )   $ 5,266     $ 372     $ (33,308 )   $ 251,957  

 

          Additional     Capital reserve
due to
translation to
    Capital reserve     Capital
reserve
from
share
    Capital
reserve
from
             
    Share     paid in     presentation     from     based     employee     Accumulated     Total  
    capital     capital     currency     hedges     payments     benefits     deficit     equity  
    Unaudited  
    U.S. Dollars in Thousands  
Balance as of January 1, 2024 (audited)   $ 15,021     $ 265,848     $ (3,490 )   $ 140     $ 6,427     $ 275     $ (40,200 )   $ 244,021  
Net income    
-
     
-
     
-
     
-
     
-
     
-
      2,365       2,365  
Other comprehensive income (loss)    
-
     
-
     
-
      (128 )    
-
      7      
-
      (121 )
Total comprehensive income (loss)    
-
     
-
     
-
      (128 )    
-
      7       2,365       2,244  
Exercise and forfeiture of share-based payment into shares     1       335      
-
     
-
      (335 )    
-
     
-
      1  
Cost of share-based payment                                     244                       244  
Balance as of March 31, 2024   $ 15,022     $ 266,183     $ (3,490 )   $ 12     $ 6,336     $ 282     $ (37,835 )   $ 246,510  

 

F-4


 

KAMADA LTD.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY

 

 

     Share     Additional
paid in
    Capital reserve
due to translation to
presentation
    Capital reserve
from
    Capital
reserve
from share
based
    Capital
reserve
from
employee
    Accumulated     Total  
    capital     capital     currency     hedges     payments     benefits     deficit     equity  
    U.S. Dollars in Thousands  
Balance as of January 1, 2024 (audited)   $ 15,021     $ 265,848     $ (3,490 )   $ 140     $ 6,427     $ 275     $ (40,200 )   $ 244,021  
Net income    
-
     
-
     
-
     
-
     
-
     
-
      14,462       14,462  
Other comprehensive income (loss), net of tax)    
-
     
-
     
-
      (89 )    
-
      89      
-
     
-
 
Total comprehensive income (loss)    
-
     
-
     
-
      (89 )    
-
      89       14,462       14,462  
Exercise and forfeiture of share-based payment into shares     7       985      
-
     
-
      (985 )    
-
     
-
      7  
Cost of share-based payment    
-
     
-
     
-
     
-
      874      
-
     
-
      874  
Income tax impact associated with issuance of shares    
-
      100      
-
     
-
                     
-
      100  
Balance as of December 31, 2024   $ 15,028     $ 266,933     $ (3,490 )   $ 51     $ 6,316     $ 364     $ (25,738 )   $ 259,464  

 

The accompanying Notes are an integral part of the Consolidated Financial Statements.

 

F-5


 

KAMADA LTD.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

 

 

    Three months period Ended     Year Ended  
    March 31,     December 31,  
    2025     2024     2024  
    Unaudited     Unaudited      
    U.S. Dollars in Thousands  
Cash Flows from Operating Activities                  
Net income (loss)   $ 3,964     $ 2,365     $ 14,462  
                         
Adjustments to reconcile net income to net cash provided by (used in) operating activities:                        
                         
Adjustments to the profit or loss items:                        
                         
Depreciation and amortization     3,611       3,237       13,808  
Financial expenses, net     1,182       1,600       6,717  
Cost of share-based payment     175       241       874  
Taxes on income     2,649       74       (1,128 )
Loss (gain) from sale of property and equipment     (8 )    
-
      11  
Change in employee benefit liabilities, net     16       (4 )     52  
      7,625       5,148       20,334  
Changes in asset and liability items:                        
                         
Decrease (increase) in trade receivables, net     (6,557 )     610       (1,977 )
Decrease (increase) in other accounts receivables     (671 )     (516 )     593  
Decrease in inventories     461       4,131       9,659  
Decrease in deferred expenses     94       112       476  
Increase (decrease) in trade payables     (3,748 )     (8,785 )     1,226  
Increase (decrease) in other accounts payables     (2,044 )     (2,051 )     1,413  
Increase (decrease) in deferred revenues     34       (122 )     23  
      (12,431 )     (6,621 )     11,413  
Cash received (paid) during the period for:                        
                         
Interest paid     (176 )     (129 )     (594 )
Interest received     534       280       2,118  
Taxes paid     (29 )     (23 )     (139 )
      329       128       1,385  
                         
Net cash provided by (used in) operating activities   $ (513 )   $ 1,020     $ 47,594  

 

F-6


 

KAMADA LTD.

 

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

 

 

    Three months period Ended     Year Ended  
    March, 31     December 31,  
    2025     2024     2024  
    Unaudited     Unaudited      
    U.S. Dollars in Thousands  
Cash Flows from Investing Activities                        
Purchase of property and equipment and intangible assets   $ (1,468 )   $ (2,682 )   $ (10,740 )
Proceeds from sale of property and equipment     8       -       1  
Net cash used in investing activities     (1,460 )     (2,682 )     (10,739 )
                         
Cash Flows from Financing Activities                        
                         
Proceeds from exercise of share base payments     46       1       7  
Proceeds from issuance of ordinary shares, net     -       -       -  
Repayment of lease liabilities     (14 )     (244 )     (1,251 )
Repayment of long-term loans     -       -       -  
Repayment of other long-term liabilities     (325 )     (5,496 )     (12,667 )
Net cash used in financing activities     (293 )     (5,739 )     (13,911 )
                         
Exchange differences on balances of cash and cash equivalent     81       (46 )     (150 )
                         
Increase (decrease) in cash and cash equivalents     (2,185 )     (7,447 )     22,794  
                         
Cash and cash equivalents at the beginning of the period     78,435       55,641       55,641  
                         
Cash and cash equivalents at the end of the period   $ 76,250     $ 48,194     $ 78,435  
                         
Significant non-cash transactions                        
Right-of-use asset recognized with corresponding lease liability   $ 352     $ 306     $ 3,304  
Purchase of property and equipment and Intangible assets   $ 1,103     $ 905     $ 1,955  

 

The accompanying Notes are an integral part of the Consolidated Financial Statements.

 

F-7


 

KAMADA LTD.

 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

 

Note 1:- General

 

General description of the Company and its activity

 

Kamada Ltd (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B® , as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the Distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second, the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third, the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with its lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial.

 

In November 2021, the Company acquired, pursuant to an Asset Purchase Agreement, CYTOGAM, WINRHO SDF, VARIZIG and HEPGAM B from Saol Therapeutics Ltd.. The acquisition of this portfolio furthered the Company’s core objective to become a fully integrated specialty plasma company with strong commercial capabilities in the U.S. market, as well as to expand to new markets, mainly in the Middle East/North Africa region, and to broaden the Company’s portfolio offering in existing markets. The Company’s wholly owned U.S. subsidiary, Kamada Inc., is responsible for the commercialization of the four products in the U.S. market, including direct sales to wholesalers and local distributers.

 

In accordance with an agreement with Takeda Pharmaceuticals Company Limited (“Takeda”), starting from the first quarter of 2022, Takeda pays the Company royalties on sales of GLASSIA manufactured by Takeda in the United States and, commencing in 2024, in Canada, at a rate of 12% on net sales through August 2025 and at a rate of 6% thereafter until 2040, with a minimum of $5 million annually for each year from 2022 to 2040. The Company will also be entitled to royalty income on sales of GLASSIA by Takeda in Australia and New Zealand, to the extent that GLASSIA will be approved, and sales will be generated in these markets by Takeda in the future.

 

The Company’s ordinary shares are listed for trading on the Tel Aviv Stock Exchange and the NASDAQ Global Select Market.

 

FIMI Opportunity Funds (“FIMI”), the leading private equity firm in Israel beneficially owns approximately 38% of the Company’s outstanding ordinary shares and is a controlling shareholder of the Company; within the meaning of the Israeli Companies Law, 1999.

 

The Company’s activity is divided into two operating segments:

 

  Proprietary Products Manufacturing, sales and distribution of plasma-derived protein therapeutics.
  Distribution Distribute imported drug products in Israel, which are manufactured by third parties.

 

The Company has four wholly-owned subsidiaries – Kamada Inc., Kamada Plasma LLC (wholly owned by Kamada Inc.), KI Biopharma LLC and Kamada Ireland Limited. In addition, the Company owns 74% of Kamada Assets Ltd. (“Kamada Assets”).

 

F-8


 

KAMADA LTD.

 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

Note 2:- Material Accounting Policies

 

  a. Basis of preparation of the interim consolidated financial statements:

 

The interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles for the preparation of financial statements for interim periods, as prescribed in IAS 34, “Interim Financial Reporting”.

 

  b. Forthcoming requirements

 

  Presentation and Disclosure in Financial Statements – IFRS 18

 

In April 2024, the IASB issued IFRS 18 Presentation and Disclosure in Financial Statements (“IFRS 18”) which replaces IAS 1 Presentation of Financial Statements. IFRS 18 requires an entity to classify all income and expenses within its statement of profit and loss into one of five categories: operating; investing; financing; income taxes; and discontinued operations. The first three categories are new. These categories are complemented by the requirement to present subtotals for “operating profit or loss,” profit or loss before financing income and taxes” and “profit or loss” IFRS 18, and the amendments to the other standards, is effective for reporting periods beginning on or after January 1, 2027, but earlier application is permitted.

 

The Company is currently assessing the impact of the Standard on its financial statements. As of March 31, 2025, the Company does not have impact on its financial statement. 

 

Note 3:- Significant events in the reporting period

 

On March 5, 2025, the company announced that its Board of Directors has declared a special cash dividend of 0.20$ (NIS 0.73) per share on the Company’s common stock (totaling $11,534 thousands). The special cash dividend was paid on April 7, 2025, to shareholders of record at the close of business on March 17, 2025.

 

F-9


 

KAMADA LTD.

 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

Note 4:- Operating Segments

 

  a. General:

 

The company has two operating segments, as follows:

 

Proprietary Products   Manufacturing, sales and distribution of plasma-derived protein therapeutics.
     
Distribution   Distribute imported drug products in Israel, which are manufactured by third parties.

  

  b. Reporting on operating segments:

 

    Three months period ended
March 31, 2025
 
    Proprietary
Products
    Distribution     Total  
    U.S Dollars in thousands  
    Unaudited  
                 
Revenues   $ 40,017     $ 4,001     $ 44,018  
Gross profit   $ 20,279     $ 470     $ 20,749  
Unallocated corporate expenses                     (12,954 )
Finance expenses, net                     (1,182 )
Income before taxes on income                   $ 6,613  

 

    Three months period ended
March 31, 2024
 
    Proprietary
Products
    Distribution     Total  
    U.S Dollars in thousands  
    Unaudited  
Revenues   $ 33,758     $ 3,978     $ 37,736  
Gross profit   $ 16,138     $ 613     $ 16,751  
Unallocated corporate expenses                     (12,712 )
Finance expenses, net                     (1,600 )
Income before taxes on income                   $ 2,439  

 

F-10


 

KAMADA LTD.

 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

Note 4:- Operating Segments (cont.)

 

  b. Reporting on operating segments (cont.):

 

    Year Ended December 31, 2024  
    Proprietary
Products
    Distribution     Total  
    U.S Dollars in thousands  
    Audited  
Revenues   $ 141,447     $ 19,506     $ 160,953  
Gross profit   $ 67,739     $ 2,228     $ 69,967  
Unallocated corporate expenses                     (49,916 )
Finance expenses, net                     (6,717 )
Income before taxes on income                   $ 13,334  

 

  c. Reporting on operating segments by geographic region:

 

    Three months period ended
March 31, 2025
 
    Proprietary
Products
    Distribution     Total  
    U.S Dollars in thousands  
    Unaudited  
Geographical markets                        
U.S.A   $ 30,157     $
-
    $ 30,157  
Israel     1,353       4,001       5,354  
Latin America     4,611      
-
      4,611  
Canada     3,036      
-
      3,036  
Asia     790      
-
      790  
Europe     70      
-
      70  
    $ 40,017     $ 4,001     $ 44,018  

 

F-11


 

KAMADA LTD.

 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

Note 4:- Operating Segments (cont.)

 

  c. Reporting on operating segments by geographic region: (cont.)

 

    Three months period ended
March 31, 2024
 
    Proprietary
Products
    Distribution     Total  
    U.S Dollars in thousands  
    Unaudited  
Geographical markets                        
U.S.A   $ 25,849     $
-
    $ $25,849  
Israel     1,832       3,978       5,810  
Canada     3,281      
-
      3,281  
Asia     1,434      
-
      1,434  
Latin America     1,116      
-
      1,116  
Europe     246      
-
      246  
    $ 33,758     $ 3,978     $ 37,736  

 

    Year ended December 31, 2024  
    Proprietary
Products
    Distribution     Total  
    U.S Dollars in thousands  
    Audited  
Geographical markets                  
U.S.A   $ 100,504     $
-
    $ 100,504  
Israel     5,506       19,506       25,012  
Latin America     18,606      
-
      18,606  
Canada     9,457      
-
      9,457  
Europe     4,936      
-
      4,936  
Asia     2,376      
-
      2,376  
Others     62      
-
      62  
    $ 141,447     $ 19,506     $ 160,953  

 

F-12


 

KAMADA LTD.

 

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

Note 5:- Financial Instruments

 

    Classification of financial instruments by fair value hierarchy

 

Financial assets (liabilities) measured at fair value 

 

    Level 1     Level 2     Level 3  
    U.S Dollars in thousands  
March 31, 2025                  
Derivatives instruments   $       -     $ (154   $ -  
Contingent consideration   $ -     $ -     $ (24,216 )
                         
March 31, 2024                        
Derivatives instruments     -     $ (91 )   $ -  
Contingent consideration   $ -     $ -     $ (24,115 )
                         
December 31, 2024                        
Derivatives instruments   $ -     $ 49     $ -  
Contingent consideration   $ -     $ -     $ (23,566 )

 

During the three months ended on March 31, 2025, there were no transfers due to the fair value measurement of any financial instrument from Level 1 to Level 2, and furthermore, there were no transfers to or from Level 3 due to the fair value measurement of any financial instrument.

 

Note 6:- Subsequent events 

 

  a. With respect to a special dividend payment made on April 7, 2025 please refer to note 3 above.

 

b. In connection with a Statement of Claim filed on June 13, 2023 against the Company by a third-party previously engaged to distribute the Company’s propriety products in Russia and Ukraine (the “Distributor”), with the tribunal of first instance in Geneva, on April 22, 2025, the tribunal dismissed the Distributer 's action and declared it inadmissible due to a lack of jurisdiction in Switzerland. The Distributer has the right to appeal such decision by May 27, 2025. For more information about this claim please refer to note 17h to the Company’s 2024 annual financial statements included in the 2024 form 20F filed with the Securities and Exchanger Commission on March 5, 2025.

 

F-13

 

2061000 0001567529 false 2025-03-31 Q1 --12-31 0001567529 2025-01-01 2025-03-31 0001567529 2025-03-31 0001567529 2024-03-31 0001567529 2024-12-31 0001567529 kmda:ProprietaryProductsMember 2025-01-01 2025-03-31 0001567529 kmda:ProprietaryProductsMember 2024-01-01 2024-03-31 0001567529 kmda:ProprietaryProductsMember 2024-01-01 2024-12-31 0001567529 kmda:DistributionMember 2025-01-01 2025-03-31 0001567529 kmda:DistributionMember 2024-01-01 2024-03-31 0001567529 kmda:DistributionMember 2024-01-01 2024-12-31 0001567529 2024-01-01 2024-03-31 0001567529 2024-01-01 2024-12-31 0001567529 ifrs-full:IssuedCapitalMember 2024-12-31 0001567529 ifrs-full:AdditionalPaidinCapitalMember 2024-12-31 0001567529 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-12-31 0001567529 ifrs-full:ReserveOfCashFlowHedgesMember 2024-12-31 0001567529 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-12-31 0001567529 ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2024-12-31 0001567529 ifrs-full:RetainedEarningsMember 2024-12-31 0001567529 ifrs-full:IssuedCapitalMember 2025-01-01 2025-03-31 0001567529 ifrs-full:AdditionalPaidinCapitalMember 2025-01-01 2025-03-31 0001567529 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-01-01 2025-03-31 0001567529 ifrs-full:ReserveOfCashFlowHedgesMember 2025-01-01 2025-03-31 0001567529 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-01-01 2025-03-31 0001567529 ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2025-01-01 2025-03-31 0001567529 ifrs-full:RetainedEarningsMember 2025-01-01 2025-03-31 0001567529 ifrs-full:IssuedCapitalMember 2025-03-31 0001567529 ifrs-full:AdditionalPaidinCapitalMember 2025-03-31 0001567529 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2025-03-31 0001567529 ifrs-full:ReserveOfCashFlowHedgesMember 2025-03-31 0001567529 ifrs-full:ReserveOfSharebasedPaymentsMember 2025-03-31 0001567529 ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2025-03-31 0001567529 ifrs-full:RetainedEarningsMember 2025-03-31 0001567529 ifrs-full:IssuedCapitalMember 2023-12-31 0001567529 ifrs-full:AdditionalPaidinCapitalMember 2023-12-31 0001567529 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2023-12-31 0001567529 ifrs-full:ReserveOfCashFlowHedgesMember 2023-12-31 0001567529 ifrs-full:ReserveOfSharebasedPaymentsMember 2023-12-31 0001567529 ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2023-12-31 0001567529 ifrs-full:RetainedEarningsMember 2023-12-31 0001567529 2023-12-31 0001567529 ifrs-full:IssuedCapitalMember 2024-01-01 2024-03-31 0001567529 ifrs-full:AdditionalPaidinCapitalMember 2024-01-01 2024-03-31 0001567529 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-01-01 2024-03-31 0001567529 ifrs-full:ReserveOfCashFlowHedgesMember 2024-01-01 2024-03-31 0001567529 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-01-01 2024-03-31 0001567529 ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2024-01-01 2024-03-31 0001567529 ifrs-full:RetainedEarningsMember 2024-01-01 2024-03-31 0001567529 ifrs-full:IssuedCapitalMember 2024-03-31 0001567529 ifrs-full:AdditionalPaidinCapitalMember 2024-03-31 0001567529 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-03-31 0001567529 ifrs-full:ReserveOfCashFlowHedgesMember 2024-03-31 0001567529 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-03-31 0001567529 ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2024-03-31 0001567529 ifrs-full:RetainedEarningsMember 2024-03-31 0001567529 ifrs-full:IssuedCapitalMember 2024-01-01 2024-12-31 0001567529 ifrs-full:AdditionalPaidinCapitalMember 2024-01-01 2024-12-31 0001567529 ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember 2024-01-01 2024-12-31 0001567529 ifrs-full:ReserveOfCashFlowHedgesMember 2024-01-01 2024-12-31 0001567529 ifrs-full:ReserveOfSharebasedPaymentsMember 2024-01-01 2024-12-31 0001567529 ifrs-full:ReserveOfRemeasurementsOfDefinedBenefitPlansMember 2024-01-01 2024-12-31 0001567529 ifrs-full:RetainedEarningsMember 2024-01-01 2024-12-31 0001567529 kmda:FIMIOpportunityFundsMember 2025-01-01 2025-03-31 0001567529 kmda:BoardOfDirectorsMember kmda:USAppendixMember 2025-03-05 2025-03-05 0001567529 2025-03-05 2025-03-05 0001567529 country:US kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:US kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:US ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:IL kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:IL kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:IL ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:OtherForeignCountriesTwoMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:OtherForeignCountriesTwoMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:OtherForeignCountriesTwoMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:CA kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:CA kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:CA ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:OtherForeignCountriesOneMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:OtherForeignCountriesOneMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:OtherForeignCountriesOneMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:EuropeOneMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:EuropeOneMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:EuropeOneMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 ifrs-full:ReportableSegmentsMember 2025-01-01 2025-03-31 0001567529 country:US kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:US kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:US ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:IL kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:IL kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:IL ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:CA kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:CA kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:CA ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:OtherForeignCountriesOneMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:OtherForeignCountriesOneMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:OtherForeignCountriesOneMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:OtherForeignCountriesTwoMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:OtherForeignCountriesTwoMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:OtherForeignCountriesTwoMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:EuropeOneMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:EuropeOneMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:EuropeOneMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 ifrs-full:ReportableSegmentsMember 2024-01-01 2024-03-31 0001567529 country:US kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:US kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:US ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:IL kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:IL kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:IL ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherForeignCountriesTwoMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherForeignCountriesTwoMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherForeignCountriesTwoMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:CA kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:CA kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 country:CA ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:EuropeOneMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:EuropeOneMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:EuropeOneMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherForeignCountriesOneMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherForeignCountriesOneMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherForeignCountriesOneMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherCountriesMember kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherCountriesMember kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:OtherCountriesMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:ProprietaryProductsMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 kmda:DistributionMember ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 ifrs-full:ReportableSegmentsMember 2024-01-01 2024-12-31 0001567529 ifrs-full:Level1OfFairValueHierarchyMember 2025-03-31 0001567529 ifrs-full:Level2OfFairValueHierarchyMember 2025-03-31 0001567529 ifrs-full:Level3OfFairValueHierarchyMember 2025-03-31 0001567529 ifrs-full:Level1OfFairValueHierarchyMember 2024-03-31 0001567529 ifrs-full:Level2OfFairValueHierarchyMember 2024-03-31 0001567529 ifrs-full:Level3OfFairValueHierarchyMember 2024-03-31 0001567529 ifrs-full:Level1OfFairValueHierarchyMember 2024-12-31 0001567529 ifrs-full:Level2OfFairValueHierarchyMember 2024-12-31 0001567529 ifrs-full:Level3OfFairValueHierarchyMember 2024-12-31 iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:ILS xbrli:shares